Amicus Therapeutics (FOLD)
(Real Time Quote from BATS)
$9.99 USD
-0.21 (-2.06%)
Updated Aug 2, 2024 03:08 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Price, Consensus and EPS Surprise
FOLD 9.99 -0.21(-2.06%)
Will FOLD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FOLD
Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?
Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
Other News for FOLD
Amicus Therapeutics to Announce Second Quarter 2024 Financial Results on August 8, 2024
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Amicus (FOLD) Gets a Buy from TD Cowen
Amicus Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
Amicus Therapeutics Receives Prix Galien U.K. Award for Pombiliti? (cipaglucosidase alfa) + Opfolda? (miglustat) as Best Pharmaceutical Product